Losses widen at Shorla Oncology
The head of Shorla Oncology said the business expects to increase revenues significantly in 2025, even as losses widened in 2023.
Chief executive Sharon Cunningham was commenting on new accounts for the Clonmel headquartered Shorla Pharma Ltd which show that the group recorded a pre-tax lopretax8.07m in 2023 as the business continued in its development phase.
The pretax loss followed a €6.2 million loss in 2022.
Last year, Sharon Cunningham and Orlaith Ryan from Shorla Oncology were named 2024 EY Entrepreneurs Of The Year.
READ MORE
Ms Cunningham said: 'Our business is very capital intensive in the product development phase. It takes several years to develop and commercialise pharmaceutical drugs to start generating revenue and realise a return''
The company is currently conducting another round of fundraising after having already raised $45 million, she added.
The accounts show that the company recorded its first revenues in 2023 at €2.49 million and Ms Cunningham said: 'There was a significant increase in revenues in 2024 and we expect another significant increase in revenues this year.'
Research and development spending increased from €2.12 million to €3.26 million in 2023.
'We are very pleased with the progress of our business and we are exactly where we planned to be and want to be from a revenue and pipeline progression perspective,' Ms Cunningham said.
The company has currently four FDA approved medicines for the US market and launched the fourth of those this week in the US.
It also has a US office at Cambridge, Massachusetts where Ms Cunningham is based.
The Waterford native said that numbers employed now total 45 and said that she expects employee numbers to increase further this year.
The accounts show a capital injection of €28.45 million in 2023 resulted in the company having shareholder funds of €17.12 million at the end of 2023.
Asked on the impact of winning the EY Entrepreneur of the Year for 2024, Ms Cunningham said that it has been ' phenomen'l'.
'It's extremely beneficial to have access to such a dynamic group of successful entrepreneurs and winning the competition overall has provided validation and further credibility of our business''
The company will be representing Ireland in the world EY Entrepreneur of the year competition in Monaco in June.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
a day ago
- Irish Times
Co-founder of Swedish internet security company named EY World Entrepreneur of the Year
Stina Ehrensvärd, co-founder of Swedish internet security company Yubico, has been named EY World Entrepreneur of the Year 2025 at an award ceremony in Monaco's Salle des Etoiles. Ms Ehrensvärd was selected from almost 5,000 participants that included 52 winners across 43 countries and jurisdictions competing for the global title. She is the fourth woman to hold the title and first winner from Sweden in the award's 25-year history. EY Ireland Entrepreneurs of the Year 2024 Sharon Cunningham and Orlaith Ryan of Shorla Oncology represented Ireland at the event. READ MORE EY said Ms Ehrensvärd built an 'industry-leading and highly profitable company that has set new standards for internet security'. She further created 'exponential growth for her company and a lasting impact on Sweden and its people'. Yubico was cofounded by Ms Ehrensvärd in 2007. Within a year, the company had launched its first physical security key for multi-factor authentication. Over the following five years, it secured work with three of the biggest technology companies in Silicon Valley. Since then, Ms Ehrensvärd has scaled Yubico to where it now protects 19 of the world's 20 largest internet companies. Its compound annual growth rate has been 40 per cent since 2020. EY chief executive Janet Truncale said Ms Ehrensvärd's 'defining philosophy that a secure digital identity is a basic human right is exactly the type of purpose-driven leadership we look to celebrate'. Ms Ehrensvärd said she was 'committed to saving the internet for democracy, for free speech, for education, for all the beautiful things we can do with it'. 'This recognition isn't the finish line,' she said. 'It's fuel. We are building a safer digital world, and I won't stop until that mission is fulfilled.' The winner was chosen by an independent panel of judges against four criteria: entrepreneurial spirit, purpose, growth and impact.
RTÉ News
27-05-2025
- RTÉ News
Poolbeg Pharma gets FDA support for POLB 001 drug
Biopharmaceutical company Poolbeg Pharma said the US Food and Drug Administration has granted Orphan Drug Designation (ODD) to its POLB 001 product as an oral preventative therapy for Cytokine Release Syndrome (CRS). Cancer immunotherapy-induced CRS is a severe side-effect that occurs in more than 70% of patients and which may lead to multi-organ failure and death. There are currently no approved preventative therapies for CRS. Poolbeg focusses on the development of innovative medicines to address unmet medical needs and its programmes target large addressable markets including, cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity. The company said the FDA grants orphan status to support the development of medicines for rare disorders affecting less than 200,000 people in the US. It provides Poolbeg with clinical development and commercialisation benefits including the potential for a seven-year period of US market exclusivity after regulatory approval of POLB 001, potential waiver exemption of Prescription Drug User Fee Act application fees and the potential for tax credits for qualifying clinical trials. Poolbeg expects the first patient to be dosed in its proposed Phase 2a in the second half of this year, with interim analysis expected in the first half of 2026 and Phase 2a topline data in the second half of 2026. Jeremy Skillington, the chief executive of Poolbeg Pharma, said that POLB 001 is potentially a breakthrough, orally delivered, preventative therapy for cancer immunotherapy-induced CRS which could significantly impact patients' lives. "We were delighted to receive Orphan Drug Designation from the FDA, which is a significant development for Poolbeg and for POLB 001, one that we believe will enhance the commercial appeal for prospective partners and help bring POLB 001 to the market faster," he said. "If approved, we believe POLB 001 has the potential to improve quality of life for patients, reduce pressure on healthcare systems, and expand access to cancer immunotherapies," the CEO added.
Irish Times
27-05-2025
- Irish Times
Poolbeg Pharma treatment gets FDA backing
The US Food and Drug Administration (FDA) has granted orphan drug designation to Poolbeg's preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (CRS). The treatment, named POLB 001, is an oral preventative therapy to treat inflammation in blood and tissues. CRS is a severe side-effect that occurs in more than 70 per cent of patients, leading to severe side-effects or death. Cytokines can sweep throughout the body and cause tissue damage and shut down circulation and other essential organs. Orphan status is granted by the FDA for to support the development of treatments for rare disorders that affect under 200,000 people in the US, and makes the development of the drug less risky for Poolbeg, with the potential for seven-year period of US market exclusivity following approval of the treatment, waiver exemption of some fees and tax credits for qualified clinical trials. READ MORE 'POLB 001 is potentially a breakthrough, orally delivered, preventative therapy for cancer immunotherapy-induced CRS which could significantly impact patients' lives,' said Poolbeg chief executive Jeremy Skillington. 'We were delighted to receive Orphan Drug Designation from the FDA, which is a significant development for Poolbeg and for POLB 001, one that we believe will enhance the commercial appeal for prospective partners and help bring POLB 001 to the market faster. If approved, we believe POLB 001 has the potential to improve quality of life for patients, reduce pressure on healthcare systems, and expand access to cancer immunotherapies.' There are currently no approved preventative therapies for CRS. The first patients are expected to get the drug in the second half of the year, as part of Poolbeg's Phase 2a trial. 'Orphan Drug Designation from the FDA underscores the urgency and importance of developing innovative therapies for this critical unmet medical need,' said Professor Brendan Buckley, Poolbeg non-executive director and a member of the scientific advisory board. 'We look forward to progressing POLB 001 in our upcoming Phase 2a clinical trial and working closely with prospective partners and regulatory agencies to bring this potential therapy to patients as quickly as possible.'
